Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Mister E who wrote (7232)	5/5/1998 9:57:00 AM
From: Andriy Turhovach	Read Replies (1) \| Respond to of 8116

Well, if this is an example of what Cytogen's newly hired PR/IR firm Russell Welsh is capable of doing (Techniclone's price went from $0.85 to $2.28 on the news) maybe miracles can happen ;-> "Tuesday May 5, 7:56 am Eastern Time Company Press Release Techniclone Reports On Publication Of Advanced Cancer Research With Vascular Targeting Technology Company's VTA Technology Exhibits Potential to Kill Cancerous Tumors By Targeting and Destroying Tumor Blood Vessels TUSTIN, Calif.--(BUSINESS WIRE)--May 5, 1998-- Techniclone Corporation (NASDAQ:TCLN - news) reported today that scientists and researchers from the University of Texas Southwestern Medical Center published results from a study investigating Vascular Endothelial Growth Factor (VEGF) as a Marker of Tumor Endothelium. These findings were published in the May 1st issue of Cancer Research. Study results indicated that several antibodies developed by the researchers had a high affinity for binding to the VEGF receptor complex, an attractive target for the specific delivery of drugs or other effector molecules to tumors. These findings demonstrated that VEGF antibodies might be ideal candidates for targeting and delivering chemical agents which may destroy the tumor by attacking the tumor's blood supply. Dr. Philip Thorpe a member of Techniclone's Scientific Advisory Board and co-author of the article stated, ''We believe Techniclone's continued research and development in the rapidly growing field of tumor angiogenesis with our patented vascular targeting agent (VTA) technology could result in new alternative therapies to treat solid tumors. There are several companies investigating methods of inhibiting the development of new blood vessels in tumors (anti-angiogenesis) with possible applications in combating the recurrence of secondary tumors. At Techniclone, we have taken an aggressive approach by targeting existing tumor blood supply in hopes of destroying established primary tumors in the body. Our research has yielded several candidates shown to eliminate large tumors in preclinical studies in animals.'' Dr. Jamie Oliver, Vice President, Clinical and Regulatory Affairs, said, ''Techniclone is committed to preparing compounds for preclinical and clinical development in the vascular targeting field. We anticipate that the clinical plans for our tumor vasculature compounds will initially be focused on the treatment of established primary tumors rather than inhibiting the growth of recurrent or secondary tumors.'' Techniclone Corporation is a biotechnology company focused on the research, development and commercialization of novel cancer therapeutics in two principal areas: 1)direct tumor targeting agents for the treatment of refractory malignant lymphomas and 2) collateral targeting agents for the treatment of solid tumors. Oncolym(R), the Company's most advanced drug development candidate, is an investigational radiolabeled murine monoclonal antibody being studied in a Phase II/III trial for the treatment of intermediate -- and high grade relapsed or refractory B-cell non-Hodgkin's lymphoma. Additionally, the company is conducting a Phase I study of its Tumor Necrosis Therapy (TNT) for the treatment of malignant glioma (brain cancer). The company is also developing additional product candidates from the following collateral targeting agents for solid tumor therapy: Vascular Targeting Agents (VTAs) and Vasopermeation Enhancement Agents (VEAs). Techniclone Corporation intends to commercialize these products through the establishment of strategic corporate collaborations. For additional company information, please visit Techniclone Corporation's web site at techniclone.com.